V Annese1, C Barcia1, F Ros-Bernal1, A Gómez1, C M Ros1, V De Pablos1, E Fernández-Villalba1, M E De Stefano1, M-T Herrero1. 1. Clinical and Experimental NeuroscienceCentro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), School of Medicine, University of Murcia, Campus de Espinardo, Murcia, SpainIstituto Pasteur-Fondazione Cenci Bolognetti, Dip. di Biologia e Biotecnologie 'Charles Darwin'Center for Research in Neurobiology 'Daniel Bovet', Sapienza Università di Roma, P.le Aldo Moro, Roma, Italy.
Abstract
AIMS: Mice and nonhuman primates administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) represent elective experimental models of Parkinsonism, in which degeneration of the nigrostriatal dopaminergic pathway is associated with prominent neuroinflammation, characterized by activated microglia and astrocytes in both substantia nigra (SN) and striatum. To date, it is unknown whether oligodendrocytes play a role in these events. METHODS: We performed a detailed qualitative and quantitative analysis of oligodendrocyte-associated changes induced by acute and chronic MPTP treatment, in the SN and striatum of mice and macaques respectively. Oligodendrocytes were immunolabelled by cell-specific markers and analysed by confocal microscopy. RESULTS: In both experimental models, MPTP treatment induces an increase in oligodendrocyte cell number and average size, as well as in the total area occupied by this cell type per tissue section, accompanied by evident morphological changes. This multifaceted array of changes, herein referred to as oligodendrogliosis, significantly correlates with the reduction in the level of dopaminergic innervation to the striatum. CONCLUSIONS: This event, associated with early damage of the dopaminergic neurone axons and of the complex striatal circuits of which they are part, may result in an important, although neglected, aspect in the onset and progression of Parkinsonism.
AIMS: Mice and nonhuman primates administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) represent elective experimental models of Parkinsonism, in which degeneration of the nigrostriatal dopaminergic pathway is associated with prominent neuroinflammation, characterized by activated microglia and astrocytes in both substantia nigra (SN) and striatum. To date, it is unknown whether oligodendrocytes play a role in these events. METHODS: We performed a detailed qualitative and quantitative analysis of oligodendrocyte-associated changes induced by acute and chronic MPTP treatment, in the SN and striatum of mice and macaques respectively. Oligodendrocytes were immunolabelled by cell-specific markers and analysed by confocal microscopy. RESULTS: In both experimental models, MPTP treatment induces an increase in oligodendrocyte cell number and average size, as well as in the total area occupied by this cell type per tissue section, accompanied by evident morphological changes. This multifaceted array of changes, herein referred to as oligodendrogliosis, significantly correlates with the reduction in the level of dopaminergic innervation to the striatum. CONCLUSIONS: This event, associated with early damage of the dopaminergic neurone axons and of the complex striatal circuits of which they are part, may result in an important, although neglected, aspect in the onset and progression of Parkinsonism.
Authors: Fillipe M de Araújo; Lorena Cuenca-Bermejo; Emiliano Fernández-Villalba; Silvia L Costa; Victor Diogenes A Silva; Maria Trinidad Herrero Journal: Cell Mol Neurobiol Date: 2021-01-02 Impact factor: 5.046
Authors: David Pamies; Daphne Wiersma; Moriah E Katt; Liang Zhao; Johannes Burtscher; Georgina Harris; Lena Smirnova; Peter C Searson; Thomas Hartung; Helena T Hogberg Journal: Neurobiol Dis Date: 2022-04-07 Impact factor: 7.046
Authors: Tcs Costa; E Fernandez-Villalba; V Izura; A M Lucas-Ochoa; N J Menezes-Filho; R C Santana; M D de Oliveira; F M Araújo; C Estrada; Vda Silva; S L Costa; M T Herrero Journal: J Neuroimmune Pharmacol Date: 2020-06-21 Impact factor: 4.147